First‐Line Osimertinib for EGFR‐Mutated Squamous Cell Lung Carcinoma: A Case Report by Yugo Matsumura, Seiya Ichihara, Kaori Nii, Kazumasa Nanjo, Naoki Kadota, Yoshio Okano, Hisanori Machida, Nobuo Hatakeyama, Hiroyuki Hino, Keishi Naruse, Tsutomu Shinohara, Shoji Sakiyama, Eiji Tacheuchi

Get full text

Pathological Complete Response to a Single Dose of Pembrolizumab‐Based Chemoimmunotherapy for Squamous Cell Carcinoma of the Lung: A Case Report by Yugo Matsumura, Seiya Ichihara, Kaori Nii, Kazumasa Nanjo, Naoki Kadota, Yoshio Okano, Hisanori Machida, Nobuo Hatakeyama, Hiroyuki Hino, Keishi Naruse, Tsutomu Shinohara, Shoji Sakiyama, Eiji Takeuchi

Get full text

Circulating Tumour DNA in Patients With EGFR‐Mutated Non‐Small‐Cell Lung Cancer and Early Disease Progression After First‐Line Osimertinib Treatment: The ELUCIDATOR Multicentre Pro... by Akihiro Tamiya, Yasuyuki Mizumori, Mitsuo Osuga, Shun‐ichi Isa, Yoshihiko Taniguchi, Keiichi Nakamura, Daijiro Harada, Tsutomu Shinohara, Hidetoshi Yanai, Katsumi Nakatomi, Masahide Oki, Masahide Mori, Tomohito Kuwako, Koji Yamazaki, Atsuhisa Tamura, Masahiko Ando, Yasuhiro Koh

Get full text

Clock pathway inhibitor overcomes tumor immune-exclusion via regulation of fibrocyte differentiation by Atsushi Mitsuhashi, Kazuya Koyama, Hirokazu Ogino, Reona Matsuo, Na Thi Nguyen, Yohei Yabuki, Ryohiko Ozaki, Yuki Tsukazaki, Yutaka Morita, Aito Yoshida, Kojin Murakami, Seidai Sato, Hiroshi Kawano, Hiroshi Nokihara, Yutaka Inagaki, Tsutomu Shinohara, Masaki Hanibuchi, Hiromitsu Takizawa, Yasuhiko Nishioka

Get full text